The nonselective nature of pan-HDAC inhibitors, which causes dose-limiting toxicities, along with the increasing evidence supporting the specific role of HDAC6 in cancer led to the development of isoform-selective inhibitors. The gene discussed is HDAC6; the disease is cancer.